van Houte Hans 4

4 · Nurix Therapeutics, Inc. · Filed Feb 10, 2026

AI-generated summary of this filing

Updated Feb 10, 2026

Nurix (NRIX) CFO Hans van Houte Receives Stock Awards

What Happened

Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), received equity awards on February 10, 2026: 93,750 derivative stock options and 42,875 restricted stock units (RSUs). The filing lists $0.00 as the acquisition price because these are company compensation grants, not open-market purchases or sales.

Key Details

Transaction date: 2026-02-10; transaction type: Award/Grant (code A); reported as derivative awards.
Award amounts: 93,750 stock options; 42,875 RSUs (total = 136,625 share-equivalents).
Price shown: $0.00 on the Form 4 (typical for grants reported as awards).
Shares owned after transaction: not disclosed in this filing.
Filing timeliness: Reported on the same date (Period of Report 2026-02-10), no late filing flag in the provided data.
Relevant footnotes:
- Options vest monthly: 1/36 of total each month beginning March 10, 2026, through Feb 9, 2029, subject to continued service.
- Each RSU equals a contingent right to one share.
- RSUs vest quarterly: 1/12 of total each quarter over three years, first vesting on July 30, 2026; shares delivered after vesting.
- RSUs do not expire; they either vest or are canceled before vest dates.

Context

These are compensation grants (not purchases or sales) intended to retain and incentivize the CFO; they do not represent immediate cash value until options are exercised or RSUs vest and shares are delivered.
For retail investors, awarded options and RSUs are common executive compensation—useful to track dilution and alignment but not a direct bullish/bearish market signal by themselves.

Form 4

Period: 2026-02-10

Chief Financial Officer

Transactions

Award
Employee Stock Option (right to buy)
[F1]
2026-02-10+93,750→ 93,750 total
Exercise: $16.45Exp: 2036-02-09→ Common Stock (93,750 underlying)
Award
Restricted Stock Units
[F2][F3][F4]
2026-02-10+42,875→ 42,875 total
Exercise: $0.00→ Common Stock (42,875 underlying)

Footnotes (4)

[F1]The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
[F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
[F3]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
[F4]RSUs do not expire; they either vest or are canceled prior to the vest date.

Signature

/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte|2026-02-10

1 file